GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (FRA:I54) » Definitions » PB Ratio

Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) PB Ratio : 6.55 (As of Apr. 02, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-04-02), Biocytogen Pharmaceuticals (Beijing) Co's share price is €1.80. Biocytogen Pharmaceuticals (Beijing) Co's Book Value per Share for the quarter that ended in Dec. 2024 was €0.28. Hence, Biocytogen Pharmaceuticals (Beijing) Co's PB Ratio of today is 6.55.

Warning Sign:

Biocytogen Pharmaceuticals (Beijing) Co Ltd stock PB Ratio (=6.65) is close to 1-year high of 7.05.

The historical rank and industry rank for Biocytogen Pharmaceuticals (Beijing) Co's PB Ratio or its related term are showing as below:

FRA:I54' s PB Ratio Range Over the Past 10 Years
Min: 2.63   Med: 4.46   Max: 8.35
Current: 6.65

During the past 5 years, Biocytogen Pharmaceuticals (Beijing) Co's highest PB Ratio was 8.35. The lowest was 2.63. And the median was 4.46.

FRA:I54's PB Ratio is ranked worse than
83.09% of 1277 companies
in the Biotechnology industry
Industry Median: 2.26 vs FRA:I54: 6.65

During the past 12 months, Biocytogen Pharmaceuticals (Beijing) Co's average Book Value Per Share Growth Rate was 3.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -16.60% per year.

During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Biocytogen Pharmaceuticals (Beijing) Co was -16.60% per year. The lowest was -20.80% per year. And the median was -18.70% per year.

Back to Basics: PB Ratio


Biocytogen Pharmaceuticals (Beijing) Co PB Ratio Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co PB Ratio Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
PB Ratio
- - 7.61 6.80 3.27

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
PB Ratio Get a 7-Day Free Trial Premium Member Only 7.61 7.74 6.80 3.34 3.27

Competitive Comparison of Biocytogen Pharmaceuticals (Beijing) Co's PB Ratio

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocytogen Pharmaceuticals (Beijing) Co's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's PB Ratio distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's PB Ratio falls into.


;
;

Biocytogen Pharmaceuticals (Beijing) Co PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Biocytogen Pharmaceuticals (Beijing) Co's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2024)
=1.80/0.275
=6.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Biocytogen Pharmaceuticals (Beijing) Co  (FRA:I54) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Biocytogen Pharmaceuticals (Beijing) Co PB Ratio Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocytogen Pharmaceuticals (Beijing) Co Business Description

Traded in Other Exchanges
Address
12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines